Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

Fineline Cube Aug 13, 2026
Company Deals

Allist Pharmaceuticals Secures Exclusive Greater China License for ArriVent’s Bispecific ADC AST12608/ARR-002

Fineline Cube Aug 13, 2026
Company Deals

Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea

Fineline Cube Aug 13, 2026
Company Deals

CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership

Fineline Cube Aug 13, 2026
Company Deals Digital

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab

Fineline Cube Aug 13, 2026
Company Drug

Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease

Fineline Cube Aug 13, 2026
Company Drug

Novartis’ Fabhalta Approved in China for C3 Glomerulopathy

Fineline Cube Apr 3, 2025

Novartis’ (NYSE: NVS) Fabhalta (iptacopan) has received approval from China’s National Medical Products Administration (NMPA)...

Company Drug

Shionogi Submits Rolling NDA for Ensitrelvir in US for COVID-19 Prophylaxis

Fineline Cube Apr 2, 2025

Shionogi announced on April 1, 2025, the initiation of a rolling New Drug Application (NDA)...

Policy / Regulatory

China’s National Health Commission Outlines Key Tasks for Primary Healthcare Reform in 2025

Fineline Cube Apr 2, 2025

The General Office of China’s National Health Commission has issued a notice outlining key tasks...

Company Drug

Pfizer Expands Abrysvo RSV Vaccine Indication to Include Ages 18-59 in EU

Fineline Cube Apr 2, 2025

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has amended the marketing...

Company Drug Legal / IP

AccurEdit’s ARTbase-A1 Base Editor Authorized by USPTO

Fineline Cube Apr 2, 2025

On April 2, 2025, China-based AccurEdit Therapeutics (Suzhou) Co., Ltd., a specialist in gene editing...

Company Deals

Organon Acquires U.S. Rights to TOFIDENCE from Biogen

Fineline Cube Apr 2, 2025

Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the...

Company Drug

Zhifei Bio’s Trivalent Influenza Vaccine Approved for Clinical Trials in China

Fineline Cube Apr 2, 2025

Zhifei Biological (SHE: 300122) announced on April 1, 2025, that its subsidiary Zhifei Longcom has...

Company Deals

ChemPartner Plans Share Issuance to Raise Up to 316.3 Million Yuan

Fineline Cube Apr 2, 2025

On April 2, 2025, ChemPartner Pharmatech (SHE: 300149) announced plans to issue shares to a...

Company Deals Medical Device

Peijia Medical and DSM-Firmenich Collaborate on Polymer Heart Valve Innovation

Fineline Cube Apr 2, 2025

Peijia Medical Technology (Suzhou) Co., Ltd. today held a strategic innovation cooperation signing ceremony and...

Company Drug

Henlius and Organon’s HLX11 Biosimilar Clears EMA Validation Hurdle

Fineline Cube Apr 2, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) announced that the European Medicines...

Company Drug

Huadong Medicine’s Semaglutide Injection Accepted for Review by China’s NMPA

Fineline Cube Apr 2, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...

Company Deals

Medtronic Partners with Methinks AI to Enhance Stroke Care in Emerging Markets

Fineline Cube Apr 2, 2025

Medtronic announced a strategic partnership with Methinks AI, a leading provider of AI-driven radiological triage...

Company Drug

Hengrui Pharmaceuticals Secures Clinical Trial Approval for HRS-9813 in IPF

Fineline Cube Apr 2, 2025

Hengrui Pharmaceuticals (SHA: 600276) announced on April 1, 2025, that its HRS-9813 capsule has received...

Company Medical Device

Sino Medical Sciences Secures Malaysian Approval for Coronary Balloon Catheter

Fineline Cube Apr 1, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving marketing approval in Malaysia...

Company Drug

Luye Pharma’s Weekly Rivastigmine Patch Approved in Japan for Alzheimer’s

Fineline Cube Apr 1, 2025

China-based Luye Pharma Group (HKG: 2186) announced that it has received marketing approval from Japan’s...

Company Drug

BeiGene’s Tevimbra Recommended for EU Approval in Small Cell Lung Cancer

Fineline Cube Apr 1, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist proposing to rename...

Company Drug

Otsuka Files FDA Application for Sibeprenlimab in IgAN Treatment

Fineline Cube Apr 1, 2025

Japan-based Otsuka Pharmaceutical Co., Ltd. announced the filing of a Biologics License Application (BLA) with...

Company

Basecare Medical Reports 44% Revenue Growth in 2024 IVF Sector

Fineline Cube Apr 1, 2025

China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has released its 2024 performance...

Company Drug

UCB’s Rystiggo Approved in China for Generalized Myasthenia Gravis

Fineline Cube Apr 1, 2025

Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from China‘’s National...

Deals Hospital

Renji Hospital Partners with Raffles Medical Group to Boost Shanghai’s Medical Tourism

Fineline Cube Apr 1, 2025

Renji Hospital, a comprehensive Class 3A hospital established in 1844 in Shanghai, has partnered with...

Posts pagination

1 … 226 227 228 … 708

Recent updates

  • AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab
  • Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease
  • Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China
  • IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform
  • Akeso’s Ivonescimab Wins NMPA Approval for First-Line Advanced Squamous Non-Small Cell Lung Cancer in Combination With Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab

Company Drug

Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease

Company Deals

Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China

Company Drug

IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.